Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
Pfizer's innovative drug palbociclib (trade name: Ibrance®) got China National Drug
Administration (CNDA) approval on July 31, 2018. Palbociclib combined with an aromatase
inhibitor can be used to treat hormone receptor-positive/human epidermal growth factor
receptor 2-negative locally advanced breast cancer or metastatic breast cancer. This brings
more treatment options for hormone receptor-positive/human epidermal growth factor receptor
2-negative locally advanced breast cancer. How to scientifically evaluate the efficacy,
tolerability, and safety of palbociclib combined with an aromatase inhibitor and to establish
a more suitable treatment strategy for Chinese patients is one of the questions that need to
be answered in clinical practice. This multi-center parallel-group randomized controlled
trial will address on this issue.